[Vemurafenib for the treatment of pediatric patients with braf v600e mutation-positive ganglioglioma]
Tapia-López E, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32017000270
Spanish
Authors' recommendations:
The evidence is of very low quality and not enough to determine the efficacy and safety of vemurafenib in pediatric patients with BRAF V600E mutation-positive ganglioglioma. One clinical practice guideline consulted mentions its use only to treat brain metastases due to melanoma with BRAF V600E mutation. The main regulatory agencies have not approved it for the treatment of BRAF V600E-positive ganglioglioma and the coverage policies consulted do not provide coverage in this type of patients.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Brain Neoplasms
- Child
- Ganglioglioma
- Humans
- Indoles
- Mutation
- Sulfonamides
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.